米氮平与阿米替林治疗抑郁症对照研究

Comparative Study on Mirtazapine and Amitriptyline in the Treatment of Depression

目的探讨米氮平治疗抑郁症的疗效及安全性。方法将60例符合CCM D-3诊断标准的抑郁症患者随机分为两组,分别给予米氮平和阿米替林治疗,疗程6周,采用汉密尔顿抑郁量表(HAM D)、汉密尔顿焦虑量表(HAMA)、临床总体评定量表(CG I)评定临床疗效,采用副反应量表(TESS)评定副反应。结果米氮平组显效率80%,阿米替林组显效率76.67%,差异无统计学意义(χ2=0.12,P>0.05),各因子分中米氮平组认知障碍减分多于阿米替林组,比较差异有显著性(t=2.72,P<0.05)。HAM D减分两组差异无统计学意义(t=1.45,P>0.05)。结论米氮平见效快,疗效肯定,副反应发生少而轻微。

Objective To determine the efficacy and safety of mirtazapine in the treatment of patients with depression.Methods A total of 60 patients who met the CCMD-3 criteria of depression disorder were treated with mirtazapine or amitriptyline for 6 weeks.The efficacy was assessed by Hamliton Depression Rating Scale（HAMD）,Hamilton Anxiety Scale（HAMA）,Clinical Global Impression（CGI） and the side effects were assessed by Treatment Emergent Symptoms Scale（TESS）.Results The significant improvement rate of mirtazapine was 80% and that of amitriptyline was 76.67%,but there was no significant difference between two groups.However,the reducing score of cognitive factor-subscale in mirtazapine group wasn’t significantly more than that in amtriptyline group.The side effects in miratazpine group were low,and the main side effects were nausea,mouth dry,headache.Conclusion Mirtazapine is an effective antidepressant,with less side effects,and it takes effect rapidly.